A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria

M. L. Volk, S. Vijan, J. A. Marrero

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

No empirical studies have defined the posttransplant survival that would justify expansion of the Milan criteria for liver transplantation of hepatocellular carcinoma. We created a Markov model comparing the survival benefit of transplantation for a patient with >Milan HCC, versus the harm caused to other patients on the waiting list. In the base-case analysis, the strategy of transplanting the patient with >Milan HCC resulted in a 44% increased risk of death and a utility loss of 3 quality-adjusted years of life across the pre- and posttransplant periods for a nationally representative cohort of patients on the waiting list. This harm outweighed the benefit of transplantation for a patient with >Milan HCC having a 5-year posttransplant survival of less than 61%. This survival threshold was most sensitive to geographic variations in organ shortage, with the threshold varying from 25% (Region 3) to >72% (Regions 1, 5, 7 and 9). In conclusion, expansion of the Milan criteria will require demonstrating high survival rates for the newly eligible patients - approximately 61% at 5 years after transplantation. In regions with less severe organ shortage, a more aggressive approach to transplanting these patients may be justified.

Original languageEnglish (US)
Pages (from-to)839-846
Number of pages8
JournalAmerican Journal of Transplantation
Volume8
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Hepatocellular Carcinoma
Waiting Lists
Survival
Transplantation
Patient Advocacy
Quality-Adjusted Life Years
Liver Transplantation
Survival Rate

Keywords

  • Ethics
  • Hepatocellular carcinoma
  • Liver transplantation
  • Public policy

ASJC Scopus subject areas

  • Immunology

Cite this

A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. / Volk, M. L.; Vijan, S.; Marrero, J. A.

In: American Journal of Transplantation, Vol. 8, No. 4, 04.2008, p. 839-846.

Research output: Contribution to journalArticle

@article{b8cfbfb7cc804ca1bd220d079e89fca9,
title = "A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria",
abstract = "No empirical studies have defined the posttransplant survival that would justify expansion of the Milan criteria for liver transplantation of hepatocellular carcinoma. We created a Markov model comparing the survival benefit of transplantation for a patient with >Milan HCC, versus the harm caused to other patients on the waiting list. In the base-case analysis, the strategy of transplanting the patient with >Milan HCC resulted in a 44{\%} increased risk of death and a utility loss of 3 quality-adjusted years of life across the pre- and posttransplant periods for a nationally representative cohort of patients on the waiting list. This harm outweighed the benefit of transplantation for a patient with >Milan HCC having a 5-year posttransplant survival of less than 61{\%}. This survival threshold was most sensitive to geographic variations in organ shortage, with the threshold varying from 25{\%} (Region 3) to >72{\%} (Regions 1, 5, 7 and 9). In conclusion, expansion of the Milan criteria will require demonstrating high survival rates for the newly eligible patients - approximately 61{\%} at 5 years after transplantation. In regions with less severe organ shortage, a more aggressive approach to transplanting these patients may be justified.",
keywords = "Ethics, Hepatocellular carcinoma, Liver transplantation, Public policy",
author = "Volk, {M. L.} and S. Vijan and Marrero, {J. A.}",
year = "2008",
month = "4",
doi = "10.1111/j.1600-6143.2007.02138.x",
language = "English (US)",
volume = "8",
pages = "839--846",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria

AU - Volk, M. L.

AU - Vijan, S.

AU - Marrero, J. A.

PY - 2008/4

Y1 - 2008/4

N2 - No empirical studies have defined the posttransplant survival that would justify expansion of the Milan criteria for liver transplantation of hepatocellular carcinoma. We created a Markov model comparing the survival benefit of transplantation for a patient with >Milan HCC, versus the harm caused to other patients on the waiting list. In the base-case analysis, the strategy of transplanting the patient with >Milan HCC resulted in a 44% increased risk of death and a utility loss of 3 quality-adjusted years of life across the pre- and posttransplant periods for a nationally representative cohort of patients on the waiting list. This harm outweighed the benefit of transplantation for a patient with >Milan HCC having a 5-year posttransplant survival of less than 61%. This survival threshold was most sensitive to geographic variations in organ shortage, with the threshold varying from 25% (Region 3) to >72% (Regions 1, 5, 7 and 9). In conclusion, expansion of the Milan criteria will require demonstrating high survival rates for the newly eligible patients - approximately 61% at 5 years after transplantation. In regions with less severe organ shortage, a more aggressive approach to transplanting these patients may be justified.

AB - No empirical studies have defined the posttransplant survival that would justify expansion of the Milan criteria for liver transplantation of hepatocellular carcinoma. We created a Markov model comparing the survival benefit of transplantation for a patient with >Milan HCC, versus the harm caused to other patients on the waiting list. In the base-case analysis, the strategy of transplanting the patient with >Milan HCC resulted in a 44% increased risk of death and a utility loss of 3 quality-adjusted years of life across the pre- and posttransplant periods for a nationally representative cohort of patients on the waiting list. This harm outweighed the benefit of transplantation for a patient with >Milan HCC having a 5-year posttransplant survival of less than 61%. This survival threshold was most sensitive to geographic variations in organ shortage, with the threshold varying from 25% (Region 3) to >72% (Regions 1, 5, 7 and 9). In conclusion, expansion of the Milan criteria will require demonstrating high survival rates for the newly eligible patients - approximately 61% at 5 years after transplantation. In regions with less severe organ shortage, a more aggressive approach to transplanting these patients may be justified.

KW - Ethics

KW - Hepatocellular carcinoma

KW - Liver transplantation

KW - Public policy

UR - http://www.scopus.com/inward/record.url?scp=40449097658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449097658&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2007.02138.x

DO - 10.1111/j.1600-6143.2007.02138.x

M3 - Article

C2 - 18318783

AN - SCOPUS:40449097658

VL - 8

SP - 839

EP - 846

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 4

ER -